<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Ginseng Res</journal-id><journal-id journal-id-type="iso-abbrev">J Ginseng Res</journal-id><journal-title-group><journal-title>Journal of Ginseng Research</journal-title></journal-title-group><issn pub-type="ppub">1226-8453</issn><issn pub-type="epub">2093-4947</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29719466</article-id><article-id pub-id-type="pmc">5925617</article-id><article-id pub-id-type="publisher-id">S1226-8453(16)30117-8</article-id><article-id pub-id-type="doi">10.1016/j.jgr.2017.03.001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Effect of high-dose ginsenoside complex (UG0712) supplementation on physical performance of healthy adults during a 12-week supervised exercise program: A randomized placebo-controlled clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Eon Sook</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yun Jun</given-names></name><email>jyang@paik.ac.kr</email><email>tamlaa@naver.com</email><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jun Hyung</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yoon</surname><given-names>Yeong Sook</given-names></name></contrib></contrib-group><aff id="aff1">Department of Family Medicine, Center for Health Promotion and Clinical Research Center, Ilsan-Paik Hospital, College of Medicine, Inje University, Goyang, Republic of Korea</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. Department of Family Medicine, Center for Health Promotion and Clinical Research Center, Ilsan-Paik Hospital, College of Medicine, Inje University, 170, Juhwa-ro, Ilsanseo-gu, Goyang-si 10380, Republic of Korea. <email>jyang@paik.ac.kr</email><email>tamlaa@naver.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>05</day><month>4</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>4</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>05</day><month>4</month><year>2017</year></pub-date><volume>42</volume><issue>2</issue><fpage>192</fpage><lpage>198</lpage><history><date date-type="received"><day>30</day><month>6</month><year>2016</year></date><date date-type="rev-recd"><day>15</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>15</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 The Korean Society of Ginseng, Published by Elsevier Korea LLC.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder/><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Background</title><p>Ginseng has been used as an ergogenic agent, although evidence for its effectiveness is weak. A randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the effect of a ginsenoside complex (UG0712) on changes in exercise performance.</p></sec><sec><title>Methods</title><p>Sedentary individuals (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;117) were randomly assigned into one of three groups: low-dose ginsenoside supplementation (100 mg/d, <italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39), high-dose ginsenoside supplementation (500 mg/d, <italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39), or a placebo group (500 mg/d, <italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39). All participants underwent a supervised 12-wk aerobic and resistance exercise training course. To assess the effects of supplementation on physical performance, maximal oxygen consumption (VO<sub>2</sub>max), anaerobic threshold (AT), lactic acid, and muscle strength of the dominant knee were measured at baseline, every visit, and after the training program.</p></sec><sec><title>Results</title><p>Both ginsenoside groups showed significant increases in VO<sub>2</sub>max and muscular strength during exercise training. There were no definite changes in AT and lactic acid levels over time. After exercise training, there were definite differences in the VO<sub>2</sub>max (28.64.9 to 33.7&#x000a0;&#x000b1;&#x000a0;4.9 ml/kg/min in high-dose group vs. 30.4&#x000a0;&#x000b1;&#x000a0;6.7 to 32.8&#x000a0;&#x000b1;&#x000a0;6.6 ml/kg/min in placebo, <italic>p</italic>&#x000a0;<italic>=</italic>&#x000a0;0.029) and AT (19.3&#x000a0;&#x000b1;&#x000a0;4.2 to 20.9&#x000a0;&#x000b1;&#x000a0;3.5 ml/kg/min in high-dose group vs. 20.0&#x000a0;&#x000b1;&#x000a0;5.1 to 20.0&#x000a0;&#x000b1;&#x000a0;4.9 ml/kg/min in placebo, <italic>p</italic>&#x000a0;<italic>=</italic>&#x000a0;0.038) between the high-dose ginsenoside and placebo groups. However, there was no difference in VO<sub>2</sub>max between the low-dose ginsenoside and placebo groups (<italic>p</italic>&#x000a0;<italic>=</italic>&#x000a0;0.254). There were no differences in muscular strength during exercise training among the three groups.</p></sec><sec><title>Conclusion</title><p>High-dose ginsenoside supplementation (UG0712) augmented the improvement of aerobic capacity by exercise training.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>cardiopulmonary exercise test</kwd><kwd>ginsenoside</kwd><kwd><italic>Panax ginseng</italic></kwd><kwd>randomized controlled trial</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">Ginseng is one of the best-selling herbal medicines in the world. Ginseng preparations are used to improve cognitive function, immunity, and vitality in East Asia <xref rid="bib1" ref-type="bibr">[1]</xref>, <xref rid="bib2" ref-type="bibr">[2]</xref>, <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>. They have also been used as ergogenic aids, which enhance physical performance and accelerate postexertional recovery <xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib6" ref-type="bibr">[6]</xref>. Ginseng products are also commonly used as ergogenic aids for athletes in the USA <xref rid="bib7" ref-type="bibr">[7]</xref>. There are many studies investigating the ergogenic action of ginseng in experimental animal studies <xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref> and clinical studies, with mixed results <xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>. Several positive results have shown that ginseng can improve physical performance <xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>; however, there is minimal research evaluating the dose differences of ginseng&#x02019;s effect.</p><p id="p0015">Liang et&#x000a0;al <xref rid="bib13" ref-type="bibr">[13]</xref> reported that administration of high-dose ginseng (1,350 mg) lowered oxygen requirement at the 24<sup>th</sup> min during endurance exercise in healthy adults. Most studies exhibiting positive effects of ginseng on physical performance were conducted using a high-dose ginseng regimen <xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>, which was suggested originally by Bucci <xref rid="bib16" ref-type="bibr">[16]</xref>. It is difficult to compare the effects of ginseng directly because the amount, quality, and composition of ginseng supplements used in previous studies are different <xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib16" ref-type="bibr">[16]</xref>, <xref rid="bib17" ref-type="bibr">[17]</xref>. The various forms of ginseng are also controversial in the assessment of ginseng&#x02019;s influence on physical performance. Ginsenosides, found exclusively in <italic>Panax ginseng</italic>, are the main active components responsible for ginseng&#x02019;s efficacy <xref rid="bib18" ref-type="bibr">[18]</xref>, <xref rid="bib19" ref-type="bibr">[19]</xref>. To clarify the ginseng effect, research using standard complexes such as G115 or ginsenosides (such as Rb1 or Rg3) has been rapidly increasing <xref rid="bib20" ref-type="bibr">[20]</xref>.</p><p id="p0020">UG0712 is a new standardized ginsenoside complex with 10% protopanaxadiol ginsenosides Rg3, Rg5, and Rk1, which is higher than the content in Korean white ginseng root (0.35%). Due to its high concentration of ginsenosides, UG0712 is thought to have a better ergogenic effect than other ginseng products.</p><p id="p0025">This 12-wk randomized, placebo-controlled trial was aimed at evaluating the efficacy and safety of daily UG0712 intake (100 mg or 500 mg), as an adjunct to aerobic and muscular exercise training, in improving the physical performance of healthy sedentary adults.</p><p id="p0030">Our hypothesis is that UG0712 might get a better augmentation effect on maximal oxygen consumption (VO<sub>2</sub>max) change by exercise training compared to placebo.</p></sec><sec id="sec2"><label>2</label><title>Participants and methods</title><sec id="sec2.1"><label>2.1</label><title>Study design</title><p id="p0035">A randomized, double-blind, placebo-controlled trial was conducted at a sports center located in the university hospital. After screening, 117 participants were randomly assigned to one of three groups: high-dose ginsenoside complex (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39); low-dose ginsenoside complex (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39); or a placebo (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39), according to a computer-generated randomization code that was provided by an independent research organization (LSK Global PS). Block randomization was used. Drug labels were applied to the capsule bottles at the distribution center to make sure all study personnel were blinded to the participant&#x02019;s study group. After randomization and baseline evaluation of physical performance, all participants visited hospital three times for follow-up exercise test. The follow-up interval was 4 wk with a 7-d window period. This trial was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines <xref rid="bib21" ref-type="bibr">[21]</xref>. The study protocol was approved by the University Hospital Institutional Review of Board (approval number IB-0708-046). All participants provided written informed consent. Double blinding was conducted for all study participants and investigators including clinicians, exercise supervisors, exercise specialists for testing, and pharmacists.</p></sec><sec id="sec2.2"><label>2.2</label><title>Participants</title><p id="p0040">The participants, who were aged&#x000a0;&#x0003e;&#x000a0;20 yr with a sedentary lifestyle, were enrolled via a standardized advertisement. We defined a sedentary lifestyle as no regular exercise or sport participation in the last 3 mo. There were 123 volunteers screened according to the exclusion criteria. Their sociodemographic factors and past medical history were noted, and physical performance tests were performed. We excluded those with obesity (body mass index&#x000a0;&#x0003e;&#x000a0;30 kg/m<sup>2</sup>), cardiovascular disease such as myocardial infarction and previous cardiac surgery, osteoarthritis, respiratory disease [Chronic obstructive pulmonary disease (COPD), asthma], and other conditions that could make exercise difficult. Participants were also free of hypothyroidism, renal disorders, hepatic disorders, pregnancy, breast-feeding, and diabetes mellitus. Participants who took drugs known to have an influence on exercise performance or recovery from postexercise fatigue (e.g., thyroxine or carnitine) 1 wk before the study entry were excluded.</p><p id="p0045">The sample size was calculated based on study of Pipat and Kanyarat <xref rid="bib6" ref-type="bibr">[6]</xref>. They reported the effect of 8-wk therapy of ginseng with exercise training on change in VO<sub>2</sub>max. Based on this result, the number of participants was generated using two-sample <italic>t</italic> test so that the study may be able to compare each of UG0713 dose groups with placebo group in terms of difference between their pre- and post-treatment levels. With 27 per group, a total of 81 participants for this study was calculated to be required for analysis of ginseng effect. Considering a 30% withdrawal rate, 117 participants were recruited, and 81 participants completed the study.<list list-type="simple" id="ulist0010"><list-item id="u0010"><p id="p0050">Hypothesis: <italic>H</italic><sub>0</sub> : <italic>&#x003b5;</italic>&#x000a0;=&#x000a0;0 versus <italic>H</italic>
<sub>&#x003b1;</sub> : <italic>&#x003b5;</italic> &#x02260; 0, where <italic>&#x003b5;</italic>&#x000a0;=&#x000a0;<italic>&#x003bc;</italic><sub>2</sub> &#x02013; <italic>&#x003bc;</italic><sub>1</sub></p></list-item><list-item id="u0015"><p id="p0055">Significance level <italic>&#x003b1;</italic>&#x000a0;=&#x000a0;0.05</p></list-item><list-item id="u0020"><p id="p0060">Test power 1&#x02212; <italic>&#x003b2;</italic>&#x000a0;=&#x000a0;0.8</p></list-item><list-item id="u0025"><p id="p0065">Change in VO<sub>2</sub>max of control group in comparison to its pretreatment level</p></list-item></list><disp-formula id="ufd1"><mml:math id="M1" altimg="si1.gif" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x000b1;</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>114.5</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>4.3</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mo>%</mml:mo><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><list list-type="simple" id="ulist0015"><list-item id="u0030"><p id="p0070">Change in VO<sub>2</sub>max of test group in comparison to its pretreatment level</p></list-item></list><disp-formula id="ufd2"><mml:math id="M2" altimg="si2.gif" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>&#x000b1;</mml:mo><mml:msub><mml:mi>&#x003c3;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>124.5</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>3.7</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mo>%</mml:mo><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><list list-type="simple" id="ulist0020"><list-item id="u0035"><p id="p0075">Pooled sample variance</p></list-item></list><disp-formula id="ufd3"><mml:math id="M3" altimg="si3.gif" overflow="scroll"><mml:mrow><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>s</mml:mi><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>s</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mi mathvariant="normal">&#x02212;</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>s</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="normal">2</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>11</mml:mn><mml:mi mathvariant="normal">&#x02212;1</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:mn>14.26</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>10</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:mn>11.70</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:mn>11</mml:mn><mml:mo>+</mml:mo><mml:mn>10</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>171.8677</mml:mn></mml:mrow></mml:math></disp-formula><list list-type="simple" id="ulist0025"><list-item id="u0040"><p id="p0080">Sample size</p></list-item></list><disp-formula id="ufd4"><mml:math id="M4" altimg="si4.gif" overflow="scroll"><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mrow><mml:mi>&#x003b1;</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi>&#x003b2;</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:msup><mml:mi>&#x003c3;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mi>&#x003b5;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1.96</mml:mn><mml:mo>+</mml:mo><mml:mn>0.84</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mn>171.87</mml:mn></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>124.5</mml:mn><mml:mi mathvariant="normal">&#x02212;</mml:mi><mml:mn>114.5</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac><mml:mo>&#x02248;</mml:mo><mml:mn>27</mml:mn></mml:mrow></mml:math></disp-formula></p></sec><sec id="sec2.3"><label>2.3</label><title>Intervention</title><p id="p0085">Eligible participants were randomly allocated into one of three groups: high-dose ginsenoside complex (UG0712, 500 mg/d), low-dose ginsenoside complex (UG0712, 100 mg/d), or a placebo (carboxy methyl cellulose, CMC 500 mg) group. The three study drugs were identical in color, shape, and taste.</p><p id="p0090">Briefly, ginseng leaf extract was purchased from Hongju Biotech Co., Ltd. (Yanbian, China). UG0712 contained partially hydrolyzed ginseng leaf extract under acidic conditions by optimizing the blending ratio of Rd and Rg3 derivatives. It was standardized to contain&#x000a0;&#x0003e;&#x000a0;5% ginsenoside Rd, and&#x000a0;&#x0003e;&#x000a0;10% ginsenoside Rg3 derivatives (Rg3, Rg5, and Rk1) which are higher than in usual ginseng. UG0712 was supplied by Unigen, Inc (Cheonan, Chugnam, Korea) <xref rid="bib22" ref-type="bibr">[22]</xref>, <xref rid="bib23" ref-type="bibr">[23]</xref>, <xref rid="bib24" ref-type="bibr">[24]</xref>. Placebo drug was CMC (500 mg). All participants were scheduled to take the drug twice/d (UG0712 250 mg twice/d in high-dose ginsenoside group, UG0712 50 mg twice per day in low-dose ginsenoside group, or CMC 250 mg twice/d in placebo group).</p><p id="p0095">The drug compliance rate was measured by a pill count method by one pharmacist. Participants with drug compliance&#x000a0;&#x0003c;&#x000a0;80% were removed from the study. The participants were not allowed to concurrently use the drugs prohibited at entry during whole period of this study.</p></sec><sec id="sec2.4"><label>2.4</label><title>Exercise training</title><p id="p0100">A 12-wk supervised exercise program was provided to all study participants. They visited a single designated training center for the exercise program. The exercise intervention consisted of the programmed exercise for 60 min/session, three times/wk. Their activities were taught and supervised by the experienced trainers according to the study guidelines. The exercise program was comprised of both aerobic and muscular strengthening exercises. Moderate intensity aerobic exercise (70% of estimated VO<sub>2</sub>max) was comprised of treadmill and cycle ergometer exercise for 30&#x02013;40 min per session. The goal of each exercise was modified by measured VO<sub>2</sub>max at every visit.</p><p id="p0105">Muscular strengthening exercise was comprised of seven types of progressive resistance training such as chest press, rowing, lateral pull-down, leg press, leg extension, leg curl, and a multi-hip exercise. After one repetition maximum of each muscle strength of was measured, all participants started training with a weight with 60&#x02013;65% of one repetition maximum for eight times and training weight was increased when the participant gained the muscular strength to endure 15 repetitions with the weight. Exercise adherence was measured using frequency of exercise at the training center. If participants had&#x000a0;&#x0003c;&#x000a0;50% of exercise compliance (&#x0003c;6 times/4 wk) at each visit, they were dropped from the study. The final physical performance evaluation was requested for all participants regardless of the drop out status.</p></sec><sec id="sec2.5"><label>2.5</label><title>Physical performance evaluations</title><p id="p0110">For assessment of the ginsenoside complex&#x02019;s effect on physical performance, we compared the changes of the physical performance measurements among the three groups. Four-time physical performance evaluations were done at baseline and at each monthly visit. Cardiopulmonary function, muscular strength of the knee, and serum levels of lactic acid were the components of the physical performance test. For cardiopulmonary function, VO<sub>2</sub>max and anaerobic threshold (AT) were measured by a modified Bruce protocol using a treadmill exercise test. It consisted of two stages of warm-up, stages of exercise, and a cool down. The increment between the exercise stages was 1&#x02013;1.5 metabolic equivalents. The goal was eliciting a submaximal exercise effect with the heart rate that was approximately 85% of the age-predicted maximum (220 minus age) at the end of the test. The test was terminated when the participants achieved the expected heart rate goal or could no longer continue exercise due to leg pain, dizziness, chest pain, systolic blood pressure drop (&#x0003e; 10 mmHg), ST elevation, or ventricular rhythm. The heart rate response to each exercise stage was monitored using an electrocardiography monitoring system (CH2000; Cambridge Heart, Cambridge, MA, USA). Oxygen uptake (VO<sub>2</sub>; ml/kg/min) was measured via open circuit spirometry using an automated gas analysis system (Quark b2; Cosmed, Pavona di Albano, Italy) after being calibrated with standard gases. VO<sub>2</sub> data were collected using breath-by-breath method during a treadmill exercise test. VO<sub>2</sub>max was calculated by the linear extrapolation of the slope of submaximal VO<sub>2</sub> and heart rate value to an estimated maximal heart rate <xref rid="bib25" ref-type="bibr">[25]</xref>. AT was automatically measured using the V-slope method (Quark b2).</p><p id="p0115">To measure the muscular strength, the isokinetic muscle strength of the dominant knee was used, because it is the main muscle of human body. Quadriceps muscle torque at 60&#x000b0; was assessed during flexion and extension of their dominant knee using an isokinetic torque machine (Cybex770 Norm; Lumex, Brooklyn, NY, USA). Serum lactic acid was measured before the treadmill test and at 20 min after the treadmill test to identify the accumulation of lactic acid during exercise. Serum lactic acid measurements (Lactate 2 generation; Roche, Basel-Stadt, Switzerland) were done at every visit. All these tests were performed in the morning, at the room that maintain the desired temperature level (22&#x000b0;) and desired humidity level (65%).</p><p id="p0120">Smoking and alcohol or caffeine intake were prohibited before each test. Heavy exercise was not allowed from one day before an exercise test to eliminate any confounding effects of the exercise. Adverse effects of UG0712 and placebo were monitored during the study period.</p></sec><sec id="sec2.6"><label>2.6</label><title>Statistical analysis</title><p id="p0125">One-way analysis of variance and a Chi-square test were used to examine the difference of the baseline characteristics among the three groups. The VO<sub>2</sub>max and AT change over time of each group were evaluated by a repeated measures (RM) one-way analysis of variance . RM analysis of covariance was used to assess differences in VO<sub>2</sub>max and AT changes among the three groups. The level of physical performance at baseline was included as a covariate. Dunnett&#x02019;s multiple comparison tests were done as a <italic>posthoc</italic> analysis to evaluate differences in physical performance between two groups. Quadriceps muscle torque and level of serum lactic acid were also evaluated using the same analysis. VO<sub>2</sub>max, AT, and muscle strength were assessed by both intention-to-treat (ITT) and per-protocol (PP) analysis. A two-sided <italic>p</italic> value&#x000a0;&#x0003c;&#x000a0;0.05 was considered to be statistically significant. Statistical analyses were done using SAS (version 9.1.3; SAS Institute, Inc., Cary, NC) or STATA (version 12 IC; Stata Corporation, College Station, TX, USA).</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><p id="p0130"><xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref> shows the process of this study. Among 123 volunteers, six were excluded by the exclusion criteria and 117 participated at entry. The participants were 85 women and 32 men with mean age 40.7&#x000a0;&#x000b1;&#x000a0;8.1 yr (range, 22&#x02013;60 yr; <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>). Of the 117 participants, 87% did no exercise at all at entry. Out of the 117 participants, 17 withdrew their consent (high-dose group&#x000a0;=&#x000a0;4, low-dose group&#x000a0;=&#x000a0;6, and placebo group&#x000a0;=&#x000a0;7). Another 19 participants dropped out during the study period because of adverse drug events (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;2), low compliance of drug intake (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;5) and exercise (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;3), and increased serum creatine kinase (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;2). Finally, 81 (69.2%) participants completed the study and were included in the PP analysis set (high-dose group&#x000a0;=&#x000a0;30, low-dose group&#x000a0;=&#x000a0;27, and placebo group&#x000a0;=&#x000a0;24). Sex, age, education, and health behavior of the three groups were not significantly different at baseline, but alcohol intake was different at baseline (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>).<fig id="fig1"><label>Fig.&#x000a0;1</label><caption><p>Flow chart of the study process.</p></caption><alt-text id="alttext0010">Fig.&#x000a0;1</alt-text><graphic xlink:href="gr1"/></fig><table-wrap id="tbl1" position="float"><label>Table&#x000a0;1</label><caption><p>Characteristics of the study population</p></caption><alt-text id="alttext0015">Table&#x000a0;1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>High-dose (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</th><th>Low-dose (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</th><th>Placebo (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</th><th><italic>p</italic><xref rid="tbl1fn1" ref-type="table-fn">1)</xref></th></tr></thead><tbody><tr><td>Age (yr)</td><td>41.05&#x000a0;&#x000b1;&#x000a0;7.19</td><td>40.18&#x000a0;&#x000b1;&#x000a0;8.54</td><td>40.92&#x000a0;&#x000b1;&#x000a0;8.61</td><td>0.878</td></tr><tr><td>Female (%)</td><td>31 (79.49)</td><td>27 (69.23)</td><td>27 (69.23)</td><td>0.503</td></tr><tr><td>Education (%)</td><td/><td/><td/><td>0.431</td></tr><tr><td>&#x000a0;&#x02264; 12 yr</td><td>14 (35.90)</td><td>9 (23.08)</td><td>13 (33.33)</td><td/></tr><tr><td>&#x000a0;&#x0003e; 12 yr</td><td>25 (64.10)</td><td>30 (76.92)</td><td>26 (66.67)</td><td/></tr><tr><td>Smoking (%)</td><td/><td/><td/><td>0.999</td></tr><tr><td>&#x000a0;Current smoker</td><td>7 (17.95)</td><td>8 (20.51)</td><td>8 (20.51)</td><td/></tr><tr><td>&#x000a0;Nonsmoker</td><td>30 (76.92)</td><td>29 (74.36)</td><td>29 (74.36)</td><td/></tr><tr><td>&#x000a0;Ex-smoker</td><td>2 (5.13)</td><td>2 (5.13)</td><td>2 (5.13)</td><td/></tr><tr><td>Alcohol (%)</td><td/><td/><td/><td>0.033</td></tr><tr><td>&#x000a0;Yes</td><td>25 (64.10)</td><td>31 (79.49)</td><td>20 (51.28)</td><td/></tr><tr><td>&#x000a0;No</td><td>14 (35.90)</td><td>8 (20.51)</td><td>19 (48.72)</td><td/></tr><tr><td>Coffee (cups/wk)</td><td>13.60&#x000a0;&#x000b1;&#x000a0;10.50</td><td>14.79&#x000a0;&#x000b1;&#x000a0;12.28</td><td>15.39&#x000a0;&#x000b1;&#x000a0;8.87</td><td>0.799</td></tr><tr><td colspan="5">Physical performance at entry</td></tr><tr><td>&#x000a0;VO<sub>2</sub>max</td><td>28.64&#x000a0;&#x000b1;&#x000a0;4.87</td><td>29.09&#x000a0;&#x000b1;&#x000a0;4.74</td><td>30.42&#x000a0;&#x000b1;&#x000a0;6.73</td><td>0.336</td></tr><tr><td>&#x000a0;AT</td><td>19.28&#x000a0;&#x000b1;&#x000a0;4.23</td><td>18.83&#x000a0;&#x000b1;&#x000a0;3.46</td><td>20.03&#x000a0;&#x000b1;&#x000a0;5.11</td><td>0.466</td></tr><tr><td colspan="5">Muscular torque of knee (60<sup>&#x000b0;</sup>)</td></tr><tr><td>&#x000a0;Right extension</td><td>102.79&#x000a0;&#x000b1;&#x000a0;29.46</td><td>110.15&#x000a0;&#x000b1;&#x000a0;39.94</td><td>119.64&#x000a0;&#x000b1;&#x000a0;47.07</td><td>0.173</td></tr><tr><td>&#x000a0;Right flexion</td><td>56.62&#x000a0;&#x000b1;&#x000a0;18.37</td><td>57.31&#x000a0;&#x000b1;&#x000a0;21.63</td><td>64.79&#x000a0;&#x000b1;&#x000a0;24.84</td><td>0.189</td></tr><tr><td>Lactic acid change after exercise</td><td>9.9&#x000a0;&#x000b1;&#x000a0;13.5</td><td>11.0&#x000a0;&#x000b1;&#x000a0;12.1</td><td>11.7&#x000a0;&#x000b1;&#x000a0;15.4</td><td>0.870</td></tr></tbody></table><table-wrap-foot><fn><p>AT, anaerobic threshold</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fn1"><label>1)</label><p id="ntpara0010">The analysis of variance test was used for comparisons between groups in age, coffee consumption amount, aerobic exercise, and physical performance at entry. The Chi-square test used for education, smoking, and alcohol</p></fn></table-wrap-foot></table-wrap></p><p id="p0135">VO<sub>2</sub>max of both high- and low-dose ginsenoside groups significantly improved during exercise training period (from 28.6&#x000a0;&#x000b1;&#x000a0;4.9 to 33.7&#x000a0;&#x000b1;&#x000a0;4.9 ml/kg/min, <italic>p&#x000a0;&#x0003c;</italic>&#x000a0;0.001 in high-dose group(<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39), from 29.1&#x000a0;&#x000b1;&#x000a0;4.7 to 33.3&#x000a0;&#x000b1;&#x000a0;6.0 mL/kg/min, <italic>p</italic>&#x000a0;<italic>=</italic>&#x000a0;0.005 in low-dose group (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39), but no significant change was observed in VO<sub>2</sub>max of the placebo group (from 30.4&#x000a0;&#x000b1;&#x000a0;6.7 to 32.8&#x000a0;&#x000b1;&#x000a0;6.6 mL/kg/min, <italic>p</italic>&#x000a0;<italic>=</italic>&#x000a0;0.474, <italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39; <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). The improvement pattern over time were also observed in quadriceps muscle torque of high- and low-dose ginsenoside groups but not in the placebo group. There were no definite AT changes during exercise in all three groups (from 19.3&#x000a0;&#x000b1;&#x000a0;4.2 to 20.9&#x000a0;&#x000b1;&#x000a0;3.5 mL/kg/min, <italic>p</italic>&#x000a0;=&#x000a0;0.238 in high-dose group, from 18.8&#x000a0;&#x000b1;&#x000a0;3.5 to 19.0&#x000a0;&#x000b1;&#x000a0;3.7 mL/kg/min, <italic>p</italic>&#x000a0;<italic>=</italic>&#x000a0;0.972 in low-dose group, and from 20.0&#x000a0;&#x000b1;&#x000a0;5.1 to 20.0&#x000a0;&#x000b1;&#x000a0;4.9 mL/kg/min, <italic>p</italic>&#x000a0;<italic>=</italic>&#x000a0;0.366, in placebo, <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). No changes over time were observed in serum lactic acid after exercise among three groups. There was no interaction between time and group (F 1.25, <italic>p</italic>&#x000a0;<italic>=</italic>&#x000a0;0.28) in RM analysis of variance model. The interaction variable was excluded in the final model.<table-wrap id="tbl2" position="float"><label>Table&#x000a0;2</label><caption><p>The effect of the ginsenoside complex on changes in physical performance and serum lactic acid during 12&#x02013;wk exercise training (ITT)<xref rid="tbl2fn3" ref-type="table-fn">3)</xref></p></caption><alt-text id="alttext0020">Table&#x000a0;2</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th>Baseline</th><th>1<sup>st</sup> follow-up</th><th>2<sup>nd</sup> follow-up</th><th>3<sup>rd</sup> follow-up</th><th><italic>p</italic></th></tr></thead><tbody><tr><td colspan="6">VO<sub>2</sub>max (mL/kg/min)</td></tr><tr><td>High-dose (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</td><td>28.6&#x000a0;&#x000b1;&#x000a0;4.9</td><td>30.8&#x000a0;&#x000b1;&#x000a0;5.2</td><td>31.6&#x000a0;&#x000b1;&#x000a0;5.00</td><td>33.7&#x000a0;&#x000b1;&#x000a0;4.9</td><td>&#x0003c;0.001<xref rid="tbl2fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>Low-dose (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</td><td>29.1&#x000a0;&#x000b1;&#x000a0;4.7</td><td>30.6&#x000a0;&#x000b1;&#x000a0;5.1</td><td>32.0&#x000a0;&#x000b1;&#x000a0;5.3</td><td>33.3&#x000a0;&#x000b1;&#x000a0;6.0</td><td>0.005<xref rid="tbl2fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>Placebo (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</td><td>30.4&#x000a0;&#x000b1;&#x000a0;6.7</td><td>31.3&#x000a0;&#x000b1;&#x000a0;6.3</td><td>31.6&#x000a0;&#x000b1;&#x000a0;6.6</td><td>32.8&#x000a0;&#x000b1;&#x000a0;6.6</td><td>0.474<xref rid="tbl2fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>High-dose versus placebo</td><td/><td/><td/><td/><td>0.029<xref rid="tbl2fn2" ref-type="table-fn">2)</xref></td></tr><tr><td>Low-dose versus placebo</td><td/><td/><td/><td/><td>0.254<xref rid="tbl2fn2" ref-type="table-fn">2)</xref></td></tr><tr><td colspan="6">Anaerobic threshold (mL/kg/min)</td></tr><tr><td>High-dose (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</td><td>19.3&#x000a0;&#x000b1;&#x000a0;4.2</td><td>19.9&#x000a0;&#x000b1;&#x000a0;3.6</td><td>20.2&#x000a0;&#x000b1;&#x000a0;2.9</td><td>20.9&#x000a0;&#x000b1;&#x000a0;3.5</td><td>0.238<xref rid="tbl2fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>Low-dose (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</td><td>18.8&#x000a0;&#x000b1;&#x000a0;3.5</td><td>19.0&#x000a0;&#x000b1;&#x000a0;3.1</td><td>19.0&#x000a0;&#x000b1;&#x000a0;3.5</td><td>19.0&#x000a0;&#x000b1;&#x000a0;3.7</td><td>0.972<xref rid="tbl2fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>Placebo (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</td><td>20.0&#x000a0;&#x000b1;&#x000a0;5.1</td><td>19.2&#x000a0;&#x000b1;&#x000a0;4.0</td><td>19.3&#x000a0;&#x000b1;&#x000a0;3.6</td><td>20.0&#x000a0;&#x000b1;&#x000a0;4.9</td><td>0.366<xref rid="tbl2fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>High-dose versus placebo</td><td/><td/><td/><td/><td>0.038<xref rid="tbl2fn2" ref-type="table-fn">2)</xref></td></tr><tr><td>Low-dose versus placebo</td><td/><td/><td/><td/><td>0.963<xref rid="tbl2fn2" ref-type="table-fn">2)</xref></td></tr><tr><td colspan="6">Muscular strength (Nm) at 60&#x000b0; during flexion of dominant knee</td></tr><tr><td>High-dose (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</td><td>56.6&#x000a0;&#x000b1;&#x000a0;18.4</td><td>61.5&#x000a0;&#x000b1;&#x000a0;20.1</td><td>68.5&#x000a0;&#x000b1;&#x000a0;22.5</td><td>69.4&#x000a0;&#x000b1;&#x000a0;22.8</td><td>0.024<xref rid="tbl2fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>Low-dose (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</td><td>57.3&#x000a0;&#x000b1;&#x000a0;21.6</td><td>63.4&#x000a0;&#x000b1;&#x000a0;22.4</td><td>68.2&#x000a0;&#x000b1;&#x000a0;24.5</td><td>71.2&#x000a0;&#x000b1;&#x000a0;25.4</td><td>0.055<xref rid="tbl2fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>Placebo (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</td><td>64.8&#x000a0;&#x000b1;&#x000a0;24.8</td><td>67.2&#x000a0;&#x000b1;&#x000a0;23.6</td><td>72.4&#x000a0;&#x000b1;&#x000a0;25.1</td><td>72.8&#x000a0;&#x000b1;&#x000a0;24.5</td><td>0.393<xref rid="tbl2fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>High-dose versus placebo</td><td/><td/><td/><td/><td>0.319<xref rid="tbl2fn2" ref-type="table-fn">2)</xref></td></tr><tr><td>Low-dose versus placebo</td><td/><td/><td/><td/><td>0.532<xref rid="tbl2fn2" ref-type="table-fn">2)</xref></td></tr><tr><td colspan="6">Change of lactic acid after exercise (mg/dL)</td></tr><tr><td>High-dose (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</td><td>9.5&#x000a0;&#x000b1;&#x000a0;12.9</td><td>11.7&#x000a0;&#x000b1;&#x000a0;14.8</td><td>13.0&#x000a0;&#x000b1;&#x000a0;17.2</td><td>11.2&#x000a0;&#x000b1;&#x000a0;9.8</td><td>0.726<xref rid="tbl2fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>Low-dose (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</td><td>9.1&#x000a0;&#x000b1;&#x000a0;14.1</td><td>11.5&#x000a0;&#x000b1;&#x000a0;18.3</td><td>11.2&#x000a0;&#x000b1;&#x000a0;17.9</td><td>9.9&#x000a0;&#x000b1;&#x000a0;18.2</td><td>0.917<xref rid="tbl2fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>Placebo (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</td><td>12.4&#x000a0;&#x000b1;&#x000a0;14.2</td><td>14.9&#x000a0;&#x000b1;&#x000a0;15.1</td><td>15.9&#x000a0;&#x000b1;&#x000a0;16.8</td><td>12.1&#x000a0;&#x000b1;&#x000a0;14.3</td><td>0.615<xref rid="tbl2fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>High-dose versus placebo</td><td/><td/><td/><td/><td>0.827<xref rid="tbl2fn2" ref-type="table-fn">2)</xref></td></tr><tr><td>Low-dose versus placebo</td><td/><td/><td/><td/><td>0.592<xref rid="tbl2fn2" ref-type="table-fn">2)</xref></td></tr></tbody></table><table-wrap-foot><fn id="tbl2fn1"><label>1)</label><p id="ntpara0015">Repeated-measures measures analysis of variance was used for change over time</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fn2"><label>2)</label><p id="ntpara0020">Repeated-measures analysis of covariance was used for determination of ginsenoside effect on performance change from the baseline at each visit: the covariate in the model was baseline level of each performance. Subgroup analysis was performed by Dunnett&#x02019;s multiple comparison</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fn3"><label>3)</label><p id="ntpara0025">The last observation carried forward is used for missing data</p></fn></table-wrap-foot></table-wrap></p><p id="p0140">The RM analysis of covariance with Dunnett&#x02019;s multiple comparison tests showed the difference in VO<sub>2</sub>max increase from baseline of three groups at each step. VO<sub>2</sub>max increase from baseline of the high-dose group was significantly higher than the placebo group after adjusting for baseline VO<sub>2</sub>max (<italic>p</italic>&#x000a0;<italic>=</italic>&#x000a0;0.029; <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). Although changes over time in AT of three group were subtle, we also observed higher increase from baseline in AT of the high-dose group compared with the placebo group (<italic>p</italic>&#x000a0;<italic>=</italic>&#x000a0;0.038; <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>). However, there were no differences between the low-dose ginsenoside group and placebo group in VO<sub>2</sub>max increase from baseline (<italic>p</italic>&#x000a0;<italic>=</italic>&#x000a0;0.254) and AT increase from baseline (= 0.963). The same result was seen in comparison of the high dose and low-dose ginsenoside group. Both ITT set and PP set analysis showed no difference of change during exercise training in VO<sub>2</sub>max, AT, and muscular strength among the three groups (<xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>).<table-wrap id="tbl3" position="float"><label>Table&#x000a0;3</label><caption><p>The effects of the ginsenoside complex on changes of physical performance during 12-wk exercise training (PP)</p></caption><alt-text id="alttext0025">Table&#x000a0;3</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Treatment</th><th>Baseline</th><th>1<sup>st</sup> follow-up</th><th>2<sup>nd</sup> follow-up</th><th>3<sup>rd</sup> follow-up</th><th><italic>p</italic></th></tr></thead><tbody><tr><td colspan="6">VO<sub>2</sub>max (mL/kg/min)</td></tr><tr><td>High-dose (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;30)</td><td>28.6&#x000a0;&#x000b1;&#x000a0;5.1</td><td>31.5&#x000a0;&#x000b1;&#x000a0;5.1</td><td>31.8&#x000a0;&#x000b1;&#x000a0;4.6</td><td>34.5&#x000a0;&#x000b1;&#x000a0;4.4</td><td>&#x0003c;0.001<xref rid="tbl3fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>Low-dose (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;27)</td><td>28.0&#x000a0;&#x000b1;&#x000a0;3.5</td><td>30.0&#x000a0;&#x000b1;&#x000a0;4.3</td><td>32.0&#x000a0;&#x000b1;&#x000a0;4.8</td><td>33.7&#x000a0;&#x000b1;&#x000a0;5.8</td><td>&#x0003c;0.001<xref rid="tbl3fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>Placebo (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;24)</td><td>29.2&#x000a0;&#x000b1;&#x000a0;5.0</td><td>30.3&#x000a0;&#x000b1;&#x000a0;4.2</td><td>30.5&#x000a0;&#x000b1;&#x000a0;4.9</td><td>32.6&#x000a0;&#x000b1;&#x000a0;5.1</td><td>0.104<xref rid="tbl3fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>High-dose versus placebo</td><td/><td/><td/><td/><td>0.048<xref rid="tbl3fn2" ref-type="table-fn">2)</xref></td></tr><tr><td>Low-dose versus placebo</td><td/><td/><td/><td/><td>0.163<xref rid="tbl3fn2" ref-type="table-fn">2)</xref></td></tr><tr><td colspan="6">Anaerobic threshold (mL/kg/min)</td></tr><tr><td>High-dose (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;30)</td><td>19.3&#x000a0;&#x000b1;&#x000a0;4.6</td><td>20.0&#x000a0;&#x000b1;&#x000a0;3.9</td><td>20.3&#x000a0;&#x000b1;&#x000a0;2.9</td><td>21.3&#x000a0;&#x000b1;&#x000a0;3.6</td><td>0.238<xref rid="tbl3fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>Low-dose (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;27)</td><td>18.4&#x000a0;&#x000b1;&#x000a0;2.9</td><td>18.7&#x000a0;&#x000b1;&#x000a0;2.3</td><td>18.6&#x000a0;&#x000b1;&#x000a0;3.0</td><td>18.8&#x000a0;&#x000b1;&#x000a0;3.0</td><td>0.972<xref rid="tbl3fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>Placebo (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;24)</td><td>18.9&#x000a0;&#x000b1;&#x000a0;3.6</td><td>18.1&#x000a0;&#x000b1;&#x000a0;2.8</td><td>18.6&#x000a0;&#x000b1;&#x000a0;2.9</td><td>19.9&#x000a0;&#x000b1;&#x000a0;5.1</td><td>0.366<xref rid="tbl3fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>High-dose versus placebo</td><td/><td/><td/><td/><td>0.052<xref rid="tbl3fn2" ref-type="table-fn">2)</xref></td></tr><tr><td>Low-dose versus placebo</td><td/><td/><td/><td/><td>0.957<xref rid="tbl3fn2" ref-type="table-fn">2)</xref></td></tr><tr><td colspan="6">Muscular strength (Nm) at 60&#x000b0; during flexion of dominant knee</td></tr><tr><td>High-dose (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;30)</td><td>56.6&#x000a0;&#x000b1;&#x000a0;18.4</td><td>61.5&#x000a0;&#x000b1;&#x000a0;20.1</td><td>68.5&#x000a0;&#x000b1;&#x000a0;22.5</td><td>69.4&#x000a0;&#x000b1;&#x000a0;22.8</td><td>0.018<xref rid="tbl3fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>Low-dose (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;27)</td><td>57.3&#x000a0;&#x000b1;&#x000a0;21.6</td><td>63.4&#x000a0;&#x000b1;&#x000a0;22.4</td><td>68.2&#x000a0;&#x000b1;&#x000a0;24.5</td><td>71.2&#x000a0;&#x000b1;&#x000a0;25.4</td><td>0.004<xref rid="tbl3fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>Placebo (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;24)</td><td>64.8&#x000a0;&#x000b1;&#x000a0;24.8</td><td>67.2&#x000a0;&#x000b1;&#x000a0;23.6</td><td>72.4&#x000a0;&#x000b1;&#x000a0;25.1</td><td>72.8&#x000a0;&#x000b1;&#x000a0;24.5</td><td>0.177<xref rid="tbl3fn1" ref-type="table-fn">1)</xref></td></tr><tr><td>High-dose versus placebo</td><td/><td/><td/><td/><td>0.815<xref rid="tbl3fn2" ref-type="table-fn">2)</xref></td></tr><tr><td>Low-dose versus placebo</td><td/><td/><td/><td/><td>0.963<xref rid="tbl3fn2" ref-type="table-fn">2)</xref></td></tr></tbody></table><table-wrap-foot><fn id="tbl3fn1"><label>1)</label><p id="ntpara0030">Repeated-measures analysis of variance was used for change over time</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fn2"><label>2)</label><p id="ntpara0035">Repeated-measures analysis of covariance was used for determination of ginsenoside effect on performance change from the baseline at each visit: the covariate in the model was baseline level of each performance. Subgroup analysis was done by Dunnett&#x02019;s multiple comparison</p></fn></table-wrap-foot></table-wrap></p><p id="p0145">Sixteen participants (13.6%) experienced adverse events during study period (<xref rid="tbl4" ref-type="table">Table&#x000a0;4</xref>). However, most of these adverse events were mild in intensity. Most common adverse events in three groups were upper respiratory infection and knee pain. Ginsenoside group showed allergic reaction. Others included diarrhea, increased blood creatine phosphokinase and polycystic ovaries. Among the adverse events, mild pruritus in the high-dose UG0712 group was regarded as a drug-related adverse event.<table-wrap id="tbl4" position="float"><label>Table&#x000a0;4</label><caption><p>The side effects of the U0712 group or placebo group during 12 wk of exercise</p></caption><alt-text id="alttext0030">Table&#x000a0;4</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Side effects (%)</th><th>High-dose group (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</th><th>Low-dose group (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</th><th>Placebo (<italic>n</italic>&#x000a0;<italic>=</italic>&#x000a0;39)</th></tr></thead><tbody><tr><td/><td>5 (12.8)</td><td>4 (10.3)</td><td>7 (17.9)</td></tr><tr><td>Upper respiratory infection</td><td>2</td><td>1</td><td>3</td></tr><tr><td>Knee pain or headache</td><td>1</td><td>1</td><td>3</td></tr><tr><td>Skin disease or allergic reaction of skin</td><td>1</td><td>1</td><td>0</td></tr><tr><td>Others<xref rid="tbl4fn1" ref-type="table-fn">1)</xref></td><td>1</td><td>1</td><td>3</td></tr></tbody></table><table-wrap-foot><fn id="tbl4fn1"><label>1)</label><p id="ntpara0040">Other&#x000a0;=&#x000a0;diarrhea, increased blood creatine phosphokinase, and polycystic ovaries</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec4"><label>4</label><title>Discussion</title><p id="p0150">The major finding of this study is that ginsenoside supplementation had a better effect on increasing the VO<sub>2</sub> max compared to the placebo, during the 12-wk exercise training. This effect was observed only in the high-dose (500 mg) group. Our results support the hypothesis that a positive ergogenic effect is associated with ginseng supplementation in high-dosages.</p><p id="p0155">Several researchers <xref rid="bib16" ref-type="bibr">[16]</xref>, <xref rid="bib26" ref-type="bibr">[26]</xref> have suggested the theory that significant improvement in physical performance by ginseng only occurs in the studies with high-dose ginseng, relatively longer study durations (&#x0003e;&#x000a0;8&#x000a0;wk), and large numbers of participants. This ergogenic effect of high-dose ginseng has been supported by the results of recent clinical trials by Liang et&#x000a0;al <xref rid="bib13" ref-type="bibr">[13]</xref> and Kim et&#x000a0;al <xref rid="bib27" ref-type="bibr">[27]</xref>. These studies provide evidence that the different effects of ginseng may be mediated by the dose. However, they did not compare physical performance according to the dose. The strength of our study is in the comparison of high-dose and low-dose ginseng supplementation to a placebo, respectively, in the same time period. Our study showed definite evidence of an ergogenic effect of ginseng, but the effective amount of ginsenoside complex used (UG0712 500 mg/d) was relatively lower than the that of previous studies (e.g., 3 g, 6 g). This might be due to the difference in the type of ginseng used. Ginseng used in previous studies were a standard root extract (e.g., 0.35% ginsenoside in Korean white ginseng extract or 4% in G115) <xref rid="bib28" ref-type="bibr">[28]</xref> but UG0712 is a new standardized complex with a higher concentration of ginsenoside (10.01%). The amount of ginsenoside is important for the ergogenic effect.</p><p id="p0160">In this study, aerobic capacity (VO<sub>2</sub>max and AT) was significantly increased by ginseng supplementation during exercise training. Aerobic capacity has been the most important variable to prove the ergogenic effect of ginseng in previous studies. Gross et&#x000a0;al <xref rid="bib29" ref-type="bibr">[29]</xref> evaluated the effect of a ginseng extract (G115) on VO<sub>2</sub>max for 94 patients with moderately severe COPD. The patients received a placebo or 200 mg of G115 daily over a 3-month study period. VO<sub>2</sub>max increased by 38% after 3 mo of ginseng supplementation. Pipat and Kanyarat <xref rid="bib6" ref-type="bibr">[6]</xref> also reported a significant increase in VO<sub>2</sub>max after 8 wk of ginseng extract intake. These findings might be explained by the actions of ginseng, such as stabilizing blood pressure, influencing platelet aggregation <xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib30" ref-type="bibr">[30]</xref>, and improving pulmonary function <xref rid="bib29" ref-type="bibr">[29]</xref>. A recent study proposed that Rg3 can improve mitochondrial antioxidant capacity and regulate mitochondrial dynamic remodeling <xref rid="bib31" ref-type="bibr">[31]</xref>. All the mechanisms of ginseng are regarded to be associated with an enhancement of aerobic capacity, especially VO<sub>2</sub>max or oxygen uptake. Thus, these measurements might be an important indicator for the ergogenic effect of ginseng.</p><p id="p0165">There are minimal studies investigating the effect of ginseng on muscular strength, although studies investigating the effect of ginseng on muscular regeneration after damage have found mixed results <xref rid="bib32" ref-type="bibr">[32]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref>. We did not observe any difference in changes of muscular strength or serum lactic acid between the ginseng groups and placebo group during exercise training.</p><p id="p0170">It is worth noting that our study showed an additional aerobic ergogenic effect of ginseng through exercise training. Pipat and Kanyarat <xref rid="bib6" ref-type="bibr">[6]</xref> reported exercise induced effects of ginseng, but found no clear synergistic action on physical performance variables when both ginseng administration and exercise training were combined. On the contrary, our study results indicate an additional ergogenic effect of ginseng when combined with exercise training.</p><p id="p0175">The strengths of this study include its well-designed clinical trial with an ample duration, different doses of ginseng, and relatively large number of participants, which is recommended by Bucci <xref rid="bib16" ref-type="bibr">[16]</xref>. By this design, we could confirm that the ergogenic effect of ginseng is effected by the dose. Furthermore, the participants in this study were sedentary healthy people. In previous research, the ginseng effects were usually focused on athletes. Our finding, the improvement of aerobic capacity by ginseng for sedentary people, is more representative of the general population. This larger effect on sedentary participants could be supported by Gross et&#x000a0;al's study <xref rid="bib29" ref-type="bibr">[29]</xref> or by Oliynyk and Oh&#x02019;s review <xref rid="bib26" ref-type="bibr">[26]</xref>. Gross et&#x000a0;al <xref rid="bib29" ref-type="bibr">[29]</xref> showed ginseng&#x02019;s effect on COPD patients. Oliynyk and Oh <xref rid="bib26" ref-type="bibr">[26]</xref> suggested that the enhancement of physical capacity by ginseng is more prominent in participants with a relatively poor physical condition.</p><p id="p0180">There are important limitations of this study that should be considered. First, dropout rate of all participants was high (30.8%) and the placebo group had the highest dropout rate (38.5%). Participant withdrawal was the most common reason for dropouts from this study. Clinical trials with exercise intervention often suffer from high dropout rates that could mislead the results. However, we did not find remarkable differences in the reasons of drop out including compliance of exercise or drug ingestion between placebo group and UG0712 group and the results between the ITT and PP set analysis were consistently persisted. Based on these reasons, we can ascertain that the high dropout rate did not indicate any bias. Second, all participants were designated to conduct exercise training. Since this is critical to the study design, we could not conclude the ergogenic effect of ginseng without exercise. So, this study does not assure that UG0712 has a similar effect on VO<sub>2</sub>max by only ginseng intake and further study is necessary to confirm the independent effect of UG0712. Third, this study adopted indirect measurement for VO<sub>2</sub>max. It is well-known that direct measurement is the best way to evaluate cardiopulmonary function. However direct measurement of VO<sub>2</sub>max was based on maximal exercise tests posing a potential hazard for the participants without clear medical condition. Additionally, a previous study showed that there is no difference between direct measurement and indirect prediction of VO<sub>2</sub>max <xref rid="bib25" ref-type="bibr">[25]</xref>, thus VO<sub>2</sub>max prediction used in this study is regarded as an accurate alternative method.</p><p id="p0185">In conclusion, our results showed that high doses of ginseng supplementation could enhance aerobic capacity during exercise training.</p></sec><sec id="sec5"><title>Conflicts of interest</title><p id="p0190">None of the authors had any conflicts of interest with regard to the research described in this article. The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Scholey</surname><given-names>A.</given-names></name><name><surname>Ossoukhova</surname><given-names>A.</given-names></name><name><surname>Owen</surname><given-names>L.</given-names></name><name><surname>Ibarra</surname><given-names>A.</given-names></name><name><surname>Pipingas</surname><given-names>A.</given-names></name><name><surname>He</surname><given-names>K.</given-names></name><name><surname>Roller</surname><given-names>M.</given-names></name><name><surname>Stough</surname><given-names>C.</given-names></name></person-group><article-title>Effects of American ginseng (<italic>Panax quinquefolius</italic>) on neurocognitive function: an acute, randomised, double-blind, placebo-controlled, crossover study</article-title><source>Psychopharmacology (Berl)</source><volume>212</volume><year>2010</year><fpage>345</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">20676609</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Helms</surname><given-names>S.</given-names></name></person-group><article-title>Cancer prevention and therapeutics: <italic>Panax ginseng</italic></article-title><source>Altern Med Rev</source><volume>9</volume><year>2004</year><fpage>259</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">15387718</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Shin</surname><given-names>B.C.</given-names></name><name><surname>Lee</surname><given-names>M.S.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Ernst</surname><given-names>E.</given-names></name></person-group><article-title>Red ginseng for type 2 diabetes mellitus: a systematic review of randomized controlled trials</article-title><source>Chin J Integr Med</source><volume>17</volume><year>2011</year><fpage>937</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">22139546</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>M.Y.</given-names></name><name><surname>Kim</surname><given-names>Y.S.</given-names></name><name><surname>Bae</surname><given-names>J.H.</given-names></name><name><surname>Nah</surname><given-names>D.Y.</given-names></name><name><surname>Kim</surname><given-names>Y.K.</given-names></name><name><surname>Lee</surname><given-names>M.M.</given-names></name><name><surname>Kim</surname><given-names>H.Y.</given-names></name></person-group><article-title>Effect of Korean Red Ginseng on arterial stiffness in subjects with hypertension</article-title><source>J&#x000a0;Altern Complement Med</source><volume>17</volume><year>2011</year><fpage>45</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">21235416</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Bahrke</surname><given-names>M.S.</given-names></name><name><surname>Morgan</surname><given-names>W.P.</given-names></name><name><surname>Stegner</surname><given-names>A.</given-names></name></person-group><article-title>Is ginseng an ergogenic aid?</article-title><source>Int J Sport Nutr Exerc Metab</source><volume>19</volume><year>2009</year><fpage>298</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">19574616</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Pipat</surname><given-names>C.</given-names></name><name><surname>Kanyarat</surname><given-names>R.</given-names></name></person-group><article-title>Effects of standardized ginseng extract and exercise training on aerobic and anaerobic exercise capacities in humans</article-title><source>J&#x000a0;Ginseng Res</source><volume>19</volume><year>1995</year><fpage>93</fpage><lpage>100</lpage></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Bardia</surname><given-names>A.</given-names></name><name><surname>Nisly</surname><given-names>N.L.</given-names></name><name><surname>Zimmerman</surname><given-names>M.B.</given-names></name><name><surname>Gryzlak</surname><given-names>B.M.</given-names></name><name><surname>Wallace</surname><given-names>R.B.</given-names></name></person-group><article-title>Use of herbs among adults based on evidence-based indications: findings from the National Health Interview Survey</article-title><source>Mayo Clin Proc</source><volume>82</volume><year>2007</year><fpage>561</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">17493422</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Cabral de Oliveira</surname><given-names>A.C.</given-names></name><name><surname>Perez</surname><given-names>A.C.</given-names></name><name><surname>Prieto</surname><given-names>J.G.</given-names></name><name><surname>Duarte</surname><given-names>I.D.</given-names></name><name><surname>Alvarez</surname><given-names>A.I.</given-names></name></person-group><article-title>Protection of <italic>Panax ginseng</italic> in injured muscles after eccentric exercise</article-title><source>J&#x000a0;Ethnopharmacol</source><volume>97</volume><issue>2</issue><year>2005</year><fpage>211</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">15707754</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Pannacci</surname><given-names>M.</given-names></name><name><surname>Lucini</surname><given-names>V.</given-names></name><name><surname>Colleoni</surname><given-names>F.</given-names></name><name><surname>Martucci</surname><given-names>C.</given-names></name><name><surname>Grosso</surname><given-names>S.</given-names></name><name><surname>Sacerdote</surname><given-names>P.</given-names></name><name><surname>Scaglione</surname><given-names>F.</given-names></name></person-group><article-title><italic>Panax ginseng</italic> C.A. Mayer G115 modulates pro-inflammatory cytokine production in mice throughout the increase of macrophage toll-like receptor 4 expression during physical stress</article-title><source>Brain Behav Immun</source><volume>20</volume><year>2006</year><fpage>546</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">16469481</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>J.D.</given-names></name><name><surname>McLung</surname><given-names>J.</given-names></name><name><surname>Nelson</surname><given-names>A.G.</given-names></name><name><surname>Welsch</surname><given-names>M.</given-names></name></person-group><article-title>Ginseng supplementation does not enhance healthy young adults' peak aerobic exercise performance</article-title><source>J&#x000a0;Am Coll Nutr</source><volume>17</volume><year>1998</year><fpage>462</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">9791844</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Engels</surname><given-names>H.J.</given-names></name><name><surname>Fahlman</surname><given-names>M.M.</given-names></name><name><surname>Wirth</surname><given-names>J.C.</given-names></name></person-group><article-title>Effects of ginseng on secretory IgA, performance, and recovery from interval exercise</article-title><source>Med Sci Sports Exerc</source><volume>35</volume><year>2003</year><fpage>690</fpage><lpage>696</lpage><pub-id pub-id-type="pmid">12673155</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Kulaputana</surname><given-names>O.</given-names></name><name><surname>Thanakomsirichot</surname><given-names>S.</given-names></name><name><surname>Anomasiri</surname><given-names>W.</given-names></name></person-group><article-title>Ginseng supplementation does not change lactate threshold and physical performances in physically active Thai men</article-title><source>J&#x000a0;Med Assoc Thai</source><volume>90</volume><year>2007</year><fpage>1172</fpage><lpage>1179</lpage><pub-id pub-id-type="pmid">17624213</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>M.T.</given-names></name><name><surname>Podolka</surname><given-names>T.D.</given-names></name><name><surname>Chuang</surname><given-names>W.J.</given-names></name></person-group><article-title><italic>Panax notoginseng</italic> supplementation enhances physical performance during endurance exercise</article-title><source>J&#x000a0;Strength Cond Res</source><volume>19</volume><year>2005</year><fpage>108</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">15744902</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Pieralisi</surname><given-names>G.</given-names></name><name><surname>Ripari</surname><given-names>P.</given-names></name><name><surname>Vecchiet</surname><given-names>L.</given-names></name></person-group><article-title>Effects of a standardized ginseng extract combined with dimethylaminoethanol bitartrate, vitamins, minerals, and trace elements on physical performance during exercise</article-title><source>Clin Ther</source><volume>13</volume><year>1991</year><fpage>373</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">1954639</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>T.H.</given-names></name><name><surname>Choi</surname><given-names>T.Y.</given-names></name><name><surname>Lee</surname><given-names>M.S.</given-names></name></person-group><article-title>Ginseng for health care: a systematic review of randomized controlled trials in Korean literature</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><fpage>e59978</fpage><pub-id pub-id-type="pmid">23560064</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Bucci</surname><given-names>L.R.</given-names></name></person-group><article-title>Selected herbals and human exercise performance</article-title><source>Am J Clin Nutr</source><volume>72</volume><issue>2 Suppl</issue><year>2000</year><comment>624S&#x02013;36S</comment></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Engels</surname><given-names>H.J.</given-names></name><name><surname>Wirth</surname><given-names>J.C.</given-names></name></person-group><article-title>No ergogenic effects of ginseng (<italic>Panax ginseng</italic> C.A. Meyer) during graded maximal aerobic exercise</article-title><source>J&#x000a0;Am Diet Assoc</source><volume>97</volume><year>1997</year><fpage>1110</fpage><lpage>1115</lpage><pub-id pub-id-type="pmid">9336557</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Ding</surname><given-names>X.</given-names></name><name><surname>Gao</surname><given-names>S.</given-names></name></person-group><article-title>The anti-fatigue effect of 20(R)-ginsenoside Rg3 in mice by intranasally administration</article-title><source>Biol Pharm Bull</source><volume>31</volume><year>2008</year><fpage>2024</fpage><lpage>2027</lpage><pub-id pub-id-type="pmid">18981567</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Shan</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Qian</surname><given-names>F.</given-names></name><name><surname>Sun</surname><given-names>M.</given-names></name><name><surname>Zhu</surname><given-names>C.</given-names></name></person-group><article-title>Effect of ginsenoside Rg3 on tyrosine hydroxylase and related mechanisms in the forced swimming-induced fatigue rats</article-title><source>J&#x000a0;Ethnopharmacol</source><volume>150</volume><year>2013</year><fpage>138</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">23994341</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Jovanovski</surname><given-names>E.</given-names></name><name><surname>Bateman</surname><given-names>E.A.</given-names></name><name><surname>Bhardwaj</surname><given-names>J.</given-names></name><name><surname>Fairgrieve</surname><given-names>C.</given-names></name><name><surname>Mucalo</surname><given-names>I.</given-names></name><name><surname>Jenkins</surname><given-names>A.L.</given-names></name><name><surname>Vuksan</surname><given-names>V.</given-names></name></person-group><article-title>Effect of Rg3-enriched Korean red ginseng (<italic>Panax ginseng</italic>) on arterial stiffness and blood pressure in healthy individuals: a randomized controlled trial</article-title><source>J&#x000a0;Am Soc Hypertens</source><volume>8</volume><year>2014</year><fpage>537</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">24997863</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>World Medical Association Declaration of Helsinki</surname></name></person-group><article-title>Ethical principles for medical research involving human subjects</article-title><source>JAMA</source><volume>284</volume><year>2000</year><fpage>3043</fpage><lpage>3045</lpage><pub-id pub-id-type="pmid">11122593</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.Y.</given-names></name><name><surname>Ri</surname><given-names>Y.</given-names></name><name><surname>Do</surname><given-names>S.G.</given-names></name><name><surname>Lee</surname><given-names>Y.C.</given-names></name><name><surname>Park</surname><given-names>S.J.</given-names></name></person-group><article-title>Evaluation of the genotoxicity of ginseng leaf extract UG0712</article-title><source>Lab Anim Res</source><volume>30</volume><year>2014</year><fpage>104</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">25324871</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>W.H.</given-names></name><name><surname>Ri</surname><given-names>Y.</given-names></name><name><surname>Do</surname><given-names>S.G.</given-names></name><name><surname>Lee</surname><given-names>Y.C.</given-names></name><name><surname>Park</surname><given-names>S.J.</given-names></name></person-group><article-title>13-week subchronic toxicity study of a novel ginsenoside composition from ginseng leaves in rats</article-title><source>Lab Anim Res</source><volume>30</volume><year>2014</year><fpage>112</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">25324872</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>H.</given-names></name><name><surname>Do</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Sung</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>Y.</given-names></name><name><surname>Woo</surname><given-names>S.S.</given-names></name><name><surname>Kang</surname><given-names>J.K.</given-names></name></person-group><article-title>UG0712, A novel ginsenoside composition enhances the endurance exercise capacity and fatigue recovery</article-title><source>Lab Anim Res</source><volume>25</volume><year>2009</year><fpage>207</fpage><lpage>212</lpage></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Marsh</surname><given-names>C.E.</given-names></name></person-group><article-title>Evaluation of the American College of Sports Medicine submaximal treadmill running test for predicting VO<sub>2</sub>max</article-title><source>J&#x000a0;Strength Cond Res</source><volume>26</volume><year>2012</year><fpage>548</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">22262016</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Oliynyk</surname><given-names>S.</given-names></name><name><surname>Oh</surname><given-names>S.</given-names></name></person-group><article-title>Actoprotective effect of ginseng: improving mental and physical performance</article-title><source>J&#x000a0;Ginseng Res</source><volume>37</volume><year>2013</year><fpage>144</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">23717168</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.H.</given-names></name><name><surname>Park</surname><given-names>K.S.</given-names></name><name><surname>Chang</surname><given-names>M.J.</given-names></name><name><surname>Sung</surname><given-names>J.H.</given-names></name></person-group><article-title>Effects of <italic>Panax ginseng</italic> extract on exercise-induced oxidative stress</article-title><source>J&#x000a0;Sports Med Phys Fitness</source><volume>45</volume><year>2005</year><fpage>178</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">16355078</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Reay</surname><given-names>J.L.</given-names></name><name><surname>Scholey</surname><given-names>A.B.</given-names></name><name><surname>Kennedy</surname><given-names>D.O.</given-names></name></person-group><article-title><italic>Panax ginseng</italic> (G115) improves aspects of working memory performance and subjective ratings of calmness in healthy young adults</article-title><source>Hum Psychopharmacol</source><volume>25</volume><year>2010</year><fpage>462</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">20737519</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Gross</surname><given-names>D.</given-names></name><name><surname>Shenkman</surname><given-names>Z.</given-names></name><name><surname>Bleiberg</surname><given-names>B.</given-names></name><name><surname>Dayan</surname><given-names>M.</given-names></name><name><surname>Gittelson</surname><given-names>M.</given-names></name><name><surname>Efrat</surname><given-names>R.</given-names></name></person-group><article-title>Ginseng improves pulmonary functions and exercise capacity in patients with COPD</article-title><source>Monaldi Arch Chest Dis</source><volume>57</volume><year>2002</year><fpage>242</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">12814035</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Luo</surname><given-names>D.</given-names></name><name><surname>Zeng</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Yue</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name></person-group><article-title>Ginsenoside Rg1 inhibits platelet activation and arterial thrombosis</article-title><source>Thromb Res</source><volume>133</volume><year>2014</year><fpage>57</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">24196231</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>W.</given-names></name></person-group><article-title>Ginsenoside Rg3 improves cardiac mitochondrial population quality: mimetic exercise training</article-title><source>Biochem Biophys Res Commun</source><volume>441</volume><year>2013</year><fpage>169</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">24140059</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Pumpa</surname><given-names>K.L.</given-names></name><name><surname>Fallon</surname><given-names>K.E.</given-names></name><name><surname>Bensoussan</surname><given-names>A.</given-names></name><name><surname>Papalia</surname><given-names>S.</given-names></name></person-group><article-title>The effects of <italic>Panax notoginseng</italic> on delayed onset muscle soreness and muscle damage in well-trained males: a double blind randomised controlled trial</article-title><source>Complement Ther Med</source><volume>21</volume><year>2013</year><fpage>131</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">23642942</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>H.L.</given-names></name><name><surname>Kwak</surname><given-names>H.E.</given-names></name><name><surname>Kim</surname><given-names>S.S.</given-names></name><name><surname>Kim</surname><given-names>Y.C.</given-names></name><name><surname>Lee</surname><given-names>C.D.</given-names></name><name><surname>Byurn</surname><given-names>H.K.</given-names></name><name><surname>Kang</surname><given-names>H.Y.</given-names></name></person-group><article-title>Effects of <italic>Panax ginseng</italic> supplementation on muscle damage and inflammation after uphill treadmill running in humans</article-title><source>Am J Chin Med</source><volume>39</volume><year>2011</year><fpage>441</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">21598413</pub-id></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgments</title><p>We acknowledge CRO LSK Global PS, who provided the SAS program for statistical analysis. The authors&#x02019; responsibilities were as follows. ESL, YJY: actively involved in the planning of the research described herein and in writing the manuscript; JHL, YJY, and ESL: collected the data; YSY and ESL: planned and supervised the analysis. All authors contributed to and reviewed the final publication.</p><p>This study was supported by the Grant from Plant Diversity Research Center of Frontier Research Program in <funding-source id="gs1">Ministry of Education, Science and Technology</funding-source> (#PF0321204-00). UG0712 and placebo was provided by <funding-source id="gs2">UNIGEN</funding-source>. The funding organizations had no role in the design and conduct of the study; the collection, analysis, and interpretation of the data; or the preparation, review, and approval of the manuscript.</p></ack></back></article>